Press Release
TORONTO, Nov 13, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF), a leading psychedelic medicine biotech company, has announced its third quarter financial results for the three and nine months ended September 30, 2020.
Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com.
Financial Highlights (in USD)
Total assets as of September 30, 2020 were $23.7 million, including $18.2 million in cash.
Net and comprehensive loss of $8.6 million for the three months ended Sep 30,2020, and $21.4 million for the nine months ended September 30, 2020.
Press Release
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
Press Release
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update
Press Release
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
You are leaving MindMed and will be automatically redirected to ${url} in a moment.
Change your mind?
Return to Mindmed